Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Northstar Gold Signs MOU with Hunan Nonferrous Ltd. to Develop Gold Resource (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Xenetic Biosciences Inc XBIO

Healthcare Biotechnology
Xenetic Biosciences, Inc. is a biopharmaceutical company. The Company is focused on advancing immune-oncology technologies addressing hard to treat cancers. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. It is focused on advancing the... see more

Recent & Breaking News (NDAQ:XBIO)

Xenetic Biosciences CEO Delivers "2014 - The Year in Review" Update to Investors and Stakeholders

Business Wire December 18, 2014

Xenetic Biosciences Partner Completes Dosing of Second Cohort in Phase 2a Study of ErepoXen® in Patients with Chronic Kidney Disease on Dialysis

Business Wire December 2, 2014

Xenetic Biosciences Provides Update on Substantial Patent Grants and Allowances in U.S. and Worldwide

Business Wire November 25, 2014

Xenetic Biosciences Partner Completes First Patient Cohort in Phase 2 Study with MyeloXen(TM) for Multiple Sclerosis

Business Wire November 21, 2014

Xenetic Biosciences to Hold Business Update Conference Call September 23 at 6:00 a.m. Eastern Time

Business Wire September 22, 2014

Xenetic Biosciences Announces Ongoing Safety and Efficacy Data From Phase 2 Trial of ErepoXen(R)

Marketwired August 11, 2014

Xenetic Biosciences Announces Ongoing Safety Data From Phase 2 Trial of ErepoXen(R)

GlobeNewswire June 30, 2014

Xenetic Biosciences Announces Dosing of First Patient on Dialysis in Phase 2a Clinical Study of ErepoXen(R)

GlobeNewswire June 11, 2014

Xenetic Biosciences Strengthens Technology Patent Portfolio

GlobeNewswire June 9, 2014

Xenetic Biosciences to Present at the Third Annual Marcum MicroCap Conference

GlobeNewswire May 29, 2014

Xenetic Biosciences Announces First Quarter 2014 Financial Results and Business Update

GlobeNewswire May 21, 2014

Xenetic Biosciences Announces Positive Phase 1 Clinical Results for PSA-Oxyntomodulin for the Treatment of Type II Diabetes and Obesity

GlobeNewswire May 12, 2014

Xenetic Biosciences Appoints Industry Veteran Mark Leuchtenberger as Chairman of the Board of Directors

GlobeNewswire May 5, 2014